Vivo Capital logo

Vivo Capital

North America, California, United States, Palo Alto

Description

Vivo is a global investment firm focused on healthcare with approximately $5.8 billion in AUM

Investor Profile

Vivo Capital has made 213 investments, with 12 in the past 12 months and 26% as lead.

Stage Focus

  • Post Ipo Equity (22%)
  • Series B (20%)
  • Series A (18%)
  • Series C (18%)
  • Series D (9%)
  • Series Unknown (7%)
  • Private Equity (3%)
  • Series E (2%)
  • Seed (1%)

Country Focus

  • United States (79%)
  • China (11%)
  • United Kingdom (3%)
  • Canada (2%)
  • Singapore (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Medical
  • Biopharma
  • Medical Device
  • Oncology
  • Life Science
  • Manufacturing
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Vivo Capital frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 36
venBio Partners
North America, California, United States, San Francisco
Co-Investments: 20
Sofinnova Investments
North America, California, United States, Menlo Park
Co-Investments: 19
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 15
CA
North America, Massachusetts, United States, Boston
Co-Investments: 20
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 39
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 17
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 28
Lilly Asia Ventures
Asia, Shanghai, China, Shanghai
Co-Investments: 19
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 16

Which angels does Vivo Capital often collaborate with?

ME
Europe, England, United Kingdom
Shared Deals: 1
FM
North America, California, United States, Mountain View
Shared Deals: 2
Shared Deals: 2
AU
Europe, Hallands Lan, Sweden, Kungsbacka
Shared Deals: 1
Mark W. Hahn
North America, North Carolina, United States, Chapel Hill
Shared Deals: 1
VR
North America, California, United States, San Francisco
Shared Deals: 1
VS
North America, Massachusetts, United States, Boston
Shared Deals: 1
GB
Europe, England, United Kingdom, London
Shared Deals: 2
David Zaccardelli
North America, United States
Shared Deals: 1
DE
Europe, Zurich, Switzerland, Zürich
Shared Deals: 1

What are some of recent deals done by Vivo Capital?

ORIC Pharmaceuticals

South San Francisco, California, United States

ORIC Pharmaceuticals is a biopharmaceutical company that develops treatments that target the causes of therapeutic resistance.

BiopharmaBiotechnologyHealth CarePharmaceuticalTherapeutics
Post Ipo EquityMay 28, 2025
Amount Raised: $125,000,000
CytomX Therapeutics

South San Francisco, California, United States

CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies.

BiotechnologyHealth CarePharmaceuticalTherapeutics
Post Ipo EquityMay 12, 2025
Amount Raised: $100,000,000
Surrozen

South San Francisco, California, United States

Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.

BiotechnologyEmergency MedicineHealth Care
Post Ipo EquityMar 24, 2025
Amount Raised: $175,000,000
Chentai New Materials

Suzhou, Jiangsu, China

Chentai New Materials integrates the R&D, design, manufacturing, and sales of high-performance composite ceramics.

Innovation ManagementManufacturingMedicalSales
Series ADec 16, 2024
Amount Raised: $13,729,663
Trevi Therapeutics

Sandy Hook, Connecticut, United States

Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.

BiotechnologyHealth CarePharmaceutical
Post Ipo EquityDec 16, 2024
Amount Raised: $50,000,000
35Pharma

Montreal, Quebec, Canada

35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.

BiopharmaBiotechnologyPharmaceutical
Series CNov 26, 2024
Amount Raised: $53,000,000
Cidara Therapeutics

San Diego, California, United States

Cidara Therapeutics is a biotechnology company that specializes in the fields of healthcare and therapeutics.

BiotechnologyHealth CareTherapeutics
Post Ipo EquityNov 21, 2024
Amount Raised: $105,000,000
Aclaris Therapeutics

Malvern, Pennsylvania, United States

Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.

BiotechnologyPharmaceuticalTherapeutics
Post Ipo EquityNov 18, 2024
Amount Raised: $80,000,000
Serán Bioscience

Bend, Oregon, United States

Serán Bioscience is a contract development and manufacturing organization.

BiotechnologyClinical TrialsManufacturingPharmaceutical
Private EquitySep 17, 2024
Amount Raised: $200,000,000
Tenax Therapeutics

Chapel Hill, North Carolina, United States

Tenax Therapeutics focuses on identifying and developing treatments that address cardiovascular and pulmonary diseases.

BiotechnologyHealth CareTherapeutics
Post Ipo EquityAug 6, 2024
Amount Raised: $100,000,000